| Description | This product is a monoclonal antibody derived from mouse, which can specifically recognize Tau. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | DB; WB; ELISA; IHC |
| Application Notes | The antibody is recommended for detection of Tau by WB, ELISA, IHC assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | Tau |
| Alternative Name | TAU; MSTD; PPND; DDPAC; MAPTL; MTBT1; MTBT2; FTDP-17; PPP1R103 |
| Research Area | Cell Biology |
Figure 1 Anti-Human Tau Monoclonal Antibody (V3S-0622-YC5485) Fab Fragment in WB
Western blot analysis of V3S-0622-YC5485 Fab fragment was performed by loading human Tau protein (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC5485 and HRP conjugated Anti-Mouse IgG (H+L) as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)
Figure 1 Anti-Human Tau Monoclonal Antibody (V3S-0622-YC5485) Fab Fragment in WB
Figure 2 Anti-Human Tau Monoclonal Antibody (V3S-0622-YC5485) Fab Fragment in DB
Dot Blot analysis of V3S-0622-YC5485 Fab fragment was performed by coating with human Tau protein (His tag).
V3S-0622-YC5485 incubation concentration: 2 μg/mL.
HRP conjugated Anti-Mouse IgG (H+L) as a secondary antibody (1: 2000)
Figure 2 Anti-Human Tau Monoclonal Antibody (V3S-0622-YC5485) Fab Fragment in DB
Figure 3 Anti-Human Tau Monoclonal Antibody (V3S-0622-YC5485) Fab Fragment in ELISA
ELISA analysis of V3S-0622-YC5485 Fab fragment was performed by coating with human Tau protein (His tag). Then blocked with BSA and incubated with V3S-0622-YC5485. The HRP conjugated Anti-Mouse IgG (H+L) as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 3 Anti-Human Tau Monoclonal Antibody (V3S-0622-YC5485) Fab Fragment in ELISA
